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Background: Periodontal disease has been associated with a number of systemic diseases. 
A high prevalence of periodontitis among individuals with chronic kidney diseases and end-
stage renal disease has been reported. However, no association between periodontal diseases 
and glomerulonephritis has previously been investigated.
Objective: The aim of this study was to assess the severity and possible role of periodontitis 
in a group of patients with unknown primary glomerulonephritis.
Methods: Ten patients with unknown primary glomerulonephritis, and who had a renal biopsy 
with stable renal function and serum creatinine ,1.6 mg/dL, were recruited. Severity of the 
periodontal disease was clinically measured with plaque index (PI), gingival index (GI), and 
periodontal pocket depth (PD). The subjects received appropriate dental treatments where 
indicated. The patients were also put on angiotensin-converting enzyme inhibitor or angiotensin 
receptor blockers for controlling blood pressure and proteinuria. Six months following 
appropriate periodontal treatment, renal function, degree of proteinuria, and level of C-reactive 
protein (CRP) were measured in each individual.
Results: The median age of the patients was 30 (15.8) years. The median urine protein excretion 
was lower following the periodontal therapy (P = 0.008). Prior to the dental and/or periodontal 
therapies, the median PI, PD, and GI were 57.5%, 4.3, and 1.1, respectively. The majority of 
the patients had advanced periodontal disease. In four patients, +2/+3 CRP turned negative 
after periodontal treatment.
Conclusions: The present study revealed that a causative link might exist between periodontal 
disease and glomerulonephritis.
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Introduction
Periodontitis, a chronic Gram-negative infection of dental supporting tissues, is consid-
ered one of the most frequent chronic infections in humans.1 The interaction between 
major periodontal microbial pathogens and inflammatory cells leads to periodontal 
disease.1 However, a number of studies have proposed an association between peri-
odontal disease and endothelial dysfunction, atherosclerosis, coronary artery disease, 
and stroke.2–4 These have been attributed to the inflammatory nature of periodontitis 
and systemic dissemination of locally produced inflammatory mediators such as inter-
leukin (IL)-1β, IL-6, and tumor necrosis factor α (TNF-α).4–6 Cell wall components 
of those microbial pathogens responsible for periodontitis might generate a response 
from the host.7 In addition, other microbial products invading the gingival and deeper 
periodontal tissues may gain access to the systemic circulation.8 These may, in turn, Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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activate the immune system, which may deregulate the lipid 
metabolism and increase the expression of cytokine-mediated 
inflammatory responses. Interestingly, predictive roles of 
inflammatory biomarkers for a poor outcome in end-stage 
renal disease have previously been highlighted.9–11
Although a high prevalence of periodontitis among 
individuals at early stages of chronic kidney diseases and 
end-stage renal disease has recently been reported,12 no 
association between periodontal diseases and glomerulo-
nephritis has   previously been investigated. Therefore, the 
present study aimed to assess the severity and possible role 
of periodontitis in a group of patients with unknown primary 
  glomerulonephritis. We also examined the long-term effect 
of periodontal treatment on the renal condition of these 
patients.
Methods
This study was carried out between May 2005 and November 
2008. Ten patients with unknown primary glomerulonephritis 
were recruited. Exclusion criteria were the presence of any 
possible causes of secondary glomerulonephritis, including 
immune complex disease, vasculitis, diabetes mellitus, or 
malignancies. To rule out the systemic disease (secondary 
glomerulonephritis), testing of the serum for the presence 
of various proteins, including human immunodeficiency 
virus (HIV), hepatitis B and C antigens, and antibodies 
(antiglomerular basement membrane, antiphospholipid, 
antineutrophil cytoplasmic antibodies, anti-DNA, cryoglobu-
lins, anti-HIV, and antihepatitis B and C antibodies) and 
depletion of complement components (C3, C4, and CH50) 
were performed.13 We included only those patients who 
had a renal biopsy with a stable renal function and serum 
creatinine ,1.6 mg/dL. An informed consent was obtained 
from the patients prior to the study.
Periodontal examination was performed by a single exam-
iner, who was unaware of the patients’ renal   pathologies. Clin-
ical measurements of the severity of the periodontal disease 
and/or health status were plaque index (PI),14 gingival index 
(GI),15 and periodontal pocket depth (PD). PI was defined as 
the amount of dental plaque on the tooth surfaces and scored 
based on a 0–100 scale. PI was performed by disclosing the 
soft debris on the tooth surfaces with a chewable tablet. GI 
was scored based on a 0–3 scale considering the assessment 
of gingival tissue inflammation and bleeding on stimula-
tion; a GI score of 0 represents a healthy gingiva.   Buccal 
surfaces of all the existing teeth were examined. Probing 
depth was performed using a periodontal probe (William’s 
Probe, Hu-Friedy, Chicago, IL, USA) at six sites in each tooth 
(mesial, central, and distal of the buccal and lingual aspects). 
The subjects received appropriate dental treatments where 
indicated. The dental treatments were aimed to eradicate the 
inflammatory/infectious diseases from the oral cavity by a 
wide variety of treatments, including oral hygiene instruc-
tion, nonsurgical or surgical periodontal therapy, systemic 
or topical medicaments, root canal therapy, and extraction, 
if needed.
Blood samples (5 mL) were taken through venipuncture 
and collected in sterile tiger top tubes and centrifuged at 
3000 rpm for 10 min at 4°C. The supernatant was frozen 
in −80°C, lyophilized for 48 h, and stored for laboratory 
  measurements. Prior to the dental procedures and 6 months 
later, serum C-reactive protein (CRP) was measured by the 
qualitative method of latex–CRP (ENiSon, ENiSon Lab, 
Tehran, Iran). Results of latex–CRP tests were reported 
according to the presence or absence of agglutination and 
size of agglutinated droplets on microscopic examination; 
no agglutination was considered negative, small-sized 
agglutinated droplets +1, medium-sized agglutinated drop-
lets +2, and large-sized agglutinated droplets +3. Serum 
creatinine was determined using commercial reagents with 
an automated chemical analyzer (Abbott Analyzer, Abbott 
Laboratories, Abbott Park, Chicago, IL, USA). Total protein 
measurement on the 24-h urine sample by a biuret colorimet-
ric assay (Cobas Integra Analyzer, F Hoffmann-La Roche, 
Basel, Switzerland) was performed on the same day as col-
lections were completed. Urine protein levels were measured 
prior to and 6 months following the treatment.
The patients were also put on angiotensin-converting 
enzyme (ACE) inhibitor (enalapril, 10–20 mg/daily) or angio-
tensin II receptor blockers (ARB) (losartan, 25–50 mg/daily) 
for controlling both the blood pressure and the proteinuria. 
Six months following appropriate periodontal treatment, 
renal function and degree of proteinuria were measured in 
each individual.
Data were presented as median (interquartile range) or 
percentage. Statistical analysis was performed with Statisti-
cal Package of Social Science (SPSS Inc, Chicago, IL, USA) 
for Windows Version 16.0 using Wilcoxon signed-rank test. 
A P value ,0.05 was considered statistically significant.
Results
Ten patients (five males and five females) were included in the 
current study. The median age of the patients was 30 (15.8) 
years. The secondary glomerulonephritis diagnostic work up 
(see Methods) was negative in all the patients. The median 
serum C3, C4, and CH50 levels were 118 mg/dL (27.5), Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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27.5 mg/dL (10), and 114% (44.5), respectively. The median 
urine protein excretion was lower following the dental 
treatments (3100 mg/day before the dental procedure vs 
900 mg/day after treatment, P = 0.008, Wilcoxon signed-
rank test, Figure 1A). Prior to the dental and/or periodontal 
therapies, the median PI, PD, and GI were 57.5% (68), 4.3 
(4.9), and 1.1 (1.2), respectively. The median serum creatinine 
level before and after the dental procedure was significantly 
different (0.95 vs 1.05 mg/dL, P = 0.048, Wilcoxon signed-
rank test, Figure 1B). Patients’ laboratory data are shown in 
Table 1. Light microscopic examination of the renal biopsies 
revealed mesangioproliferative glomerulonephritis in seven 
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Figure 1 The median A) urine protein excretion and B) serum creatinine level before and after the dental procedure (P , 0.05).Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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patients and membranoproliferative glomerulonephritis 
in two patients. C3 complement deposit was illustrated in 
five kidney biopsies (Table 2). The majority of our patients 
had advanced periodontal disease. In four patients (40%), 
+2/+3 CRP turned negative after periodontal treatment. 
Oral findings as well as the dental treatments are presented 
in Table 3.
Discussion
The present study showed a high rate of periodontal 
disease in a group of patients with unknown primary 
glomerulonephritis. Treatment of periodontal disease might 
have lowered urine protein in the present study; however, 
all patients were put on an ACE inhibitor or ARB, and these 
agents alone might be sufficient to explain the decrease 
in proteinuria. Although the current investigation did not 
include any control group in which periodontal diseases 
remained untreated, possible association between perio-
dontitis and unknown primary glomerulonephritis might 
be concluded.
Although pathogenesis of glomerulonephritis often 
remains unknown, idiopathic or primary glomerulonephritis, 
Table 1 Patients’ demographic and laboratory data (n = 10)1
Patient Age/sex Urine protein2 
(before)
Urine protein2 
(after)
Serum creatinine 
(before)
Serum creatinine 
(after)
PI (%) PD GI
1 51/M 2600 160 1.1 1.2 100 7.7 2.7
2 43/F 3000 400 0.7 0.7 70 6.8 1.7
3 30/M 3300 500 0.8 1.2 70 5 1.8
4 35/F 2600 1000 1 1.1 97 5.2 1.8
5 22/F 9800 500 0.6 0.8 90 6.7 2
6 17/F 2500 1500 1 1.2 45 1.5 0.6
7 23/M 4400 1500 0.7 0.8 17 3.7 0.6
8 37/F 3300 800 1 0.8 20 1.7 0.6
9 30/M 2900 3300 0.9 1 25 1.8 0.5
10 28/M 3200 2800 1.6 2.2 27 3.2 0.6
Notes: 1Urine protein and serum creatinine levels were recorded before and 6 months after the dental treatments; 2Twenty-four hour urinary protein excretion.
Abbreviations: F, female; gi, gingival index; M, male; PD, periodontal pocket depth; Pi, plaque index.
Table 2 Kidney biopsy results of the patients (n = 10)
Patient Renal biopsy Serum C3 
(mg/dL)
Serum C4 
(mg/dL)
Serum 
CH50 
(%)
LM IF Interstitial 
inflammation
Fibrosis
1 MP igM+, C3++ Mild mononuclear 
infiltration
Mild 120 20 101
2 MP C3++ Mild patchy mononuclear 
infiltration
none 104 21 110
3 MP igM+, C3+ Mild mononuclear 
infiltration
none 118 18 150
4 MP igg++, igA+ Moderate patchy mixed 
inflammation
none 140 22 110
5 MP igg++, C3++ Mild patchy inflammation Mild 88 30 102
6 MP igA+ none none 99 27 110
7 MCD negative Mild mononuclear 
infiltration
none 127 30 120
8 MPgn igM+, C3+ Mild patchy mononuclear 
infiltration
Mild 118 33 171
9 MPgn igA+ Mild mononuclear 
infiltration
Mild 150 35 118
10 MP, Fsgs igM+ Moderate patchy 
mononuclear infiltration
Mild 105 28 160
Note: serum complement levels prior to the dental procedures are also included. The normal range of C3 is 90–180 mg/dL, C4 is 10–40 mg/dL, and Ch50 is 70%–150%.
Abbreviations: C3, C3 complement; C4, C4 complement; CH50, total hemolytic complement; FSGS, focal segmental glomerulosclerosis; IF, immunofluorescence staining; 
igA, immunoglobulin A; igg, immunoglobulin g; igM, immunoglobulin M; LM, light microscopy; MCD, minimal change disease; MP, mesangioproliferative glomerulonephritis; 
MPgn, membranoproliferative glomerulonephritis.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
97
Periodontal disease and glomerulonephritis
many types of insult have been found to initiate the 
  glomerulonephritis. Endogenous processes, including 
autoimmunity and malignancies, and exogenous fac-
tors, such as infectious organisms and drugs, have been 
attributed to the development of glomerulonephritis.16 The 
mechanisms of glomerulonephritis have been extensively 
studied and reviewed by Chadban and Atkins,16 Cunard 
and Kelly,17 Naicker et al,18 and Hricik et al.19 Briefly, 
antibody deposition within the kidney is known to be an 
early process of glomerular inflammation in several forms 
of glomerulonephritis, including Goodpasture’s disease 
and cryoglobulinemia.16,18,20,21   Moreover, evidence from 
immunofluorescence studies has revealed that complement 
deposition within glomeruli is a key feature of many forms 
of glomerulonephritis (eg, lupus nephritis).16,18   Similarly, 
decreased levels of complement components in sera of 
patients suffering from complement-mediated glomerular 
injury imply a pathogenetic role of complement deposition 
in glomerulonephritis.16   Additionally, the role of inflamma-
tory leukocytes within both the glomerular and the interstitial 
compartments of the kidney has been highlighted in numer-
ous studies. Recruitment of the inflammatory cells, predomi-
nantly T lymphocytes and macrophages, from the circulation 
is attracted to the kidney by local release of chemokines.16,22 
The processes following mononuclear cell infiltration give 
rise to the production of more cytokines and proteases that 
can cause further kidney damage.16,23   Nevertheless, no asso-
ciation between periodontal diseases and glomerulonephritis 
has been hitherto reported. In the present study, a high rate of 
periodontal disease in patients with unknown primary glom-
erulonephritis might reveal probable association between 
periodontitis and primary glomerulonephritis through direct 
effects of periodontal pathogens and/or immune-mediated 
processes (see below).
Periodontitis is an important cause of low-grade infection 
that is commonly asymptomatic and remains undiagnosed 
for a long period of time. Meanwhile, periodontal pathogens 
are able to invade the systemic circulation.1,2 For instance, 
  Porphyromonas gingivalis, a periodontal pathogen, has 
showed an invasive trend toward endothelial cell cultures.1,24 
Hence, periodontal pathogens may directly affect the glom-
eruli. On the one hand, further studies on renal biopsy speci-
mens to find specific periodontal bacteria or antigens seem to 
be conclusive. On the other hand, periodontitis is associated 
with increased levels of inflammatory cytokines includ-
ing IL-6 and TNF-α.3 Moreover, lipopolysaccharides of 
periodontal pathogens could directly activate the toll-like 
receptors of oral epithelial cells and lead to production of 
inflammatory cytokines.25 Mitogenic effects of IL-1, IL-6, 
and TNF-α have been detected on mesangial cell and epithe-
lial cells which, in turn, induce glomerular inflammation.26,27 
TNF-α also activates the synthesis of IL-1β and IL-6 by 
glomerular mesangial cells.28 Inflammatory cytokines could 
also activate the complement system.29 It has also been shown 
that intensive periodontal therapy reduces local and systemic 
inflammation.30
In conclusion, it seems that periodontitis may be a 
neglected and treatable cause of glomerulonephritis which 
needs more consideration. The authors believe that the 
causative link between peritoneal disease and glomerulo-
nephritis might be plausible through both invasion of the 
glomeruli by periodontal pathogens, directly, and systemic 
inflammatory burden of chronic periodontitis, indirectly. 
Further investigations are recommended to be orchestrated 
in order to discover the periodontal pathogens and/or the 
level of systemic inflammatory cytokines before and after 
periodontal treatment in individuals with unknown primary 
glomerulonephritis.
Table 3 Oral findings and dental treatments in the patients (n = 10)
Patient Oral findings1 Dental treatments CRP2 (before) CRP2 (after)
1 severe periodontitis Ohi, PeriT, eXT +3 negative
2 severe periodontitis, periapical infections Ohi, PeriT, eXT, RCT +3 negative
3 Periodontitis, ill-prepared RCT Ohi, PeriT, re-RCT +1 negative
4 Periodontitis, infectious roots remaining  Ohi, PeriT, eXT +1 +1
5 Periodontitis, active dental abscess Ohi, PeriT, eXT +3 negative
6 gingivitis, no active infectious foci Ohi +1 +1
7 gingivitis, no active infectious foci Ohi negative negative
8 gingivitis, ill-prepared RCT Ohi, re-RCT +1 negative
9 gingivitis, no active infectious foci Ohi +1 negative
10 gingivitis, periapical infections Ohi, eXT +2 negative
Notes: CRP levels before and after dental procedures are also included. 1Oral findings have been recorded prior to the dental treatments; 2CRP levels have been measured 
before and 6 months after periodontal therapy.
Abbreviations: CRP, C-reactive protein; eXT, tooth extraction; Ohi, oral hygiene instruction; PeriT, periodontal treatments; RCT, root canal therapy.Therapeutics and Clinical Risk Management
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